These 20 stocks are strong choices for momentum investors

“Big mo” is an “eternal feature” of financial markets worldwide.

Market Watch • Jan 22, 2026

Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too

Inhibrx Biosciences, Inc. remains a Strong Buy, driven by multiple near-term catalysts, notably the Q2 2026 BLA filing for ozekibart in chondrosarcoma. INBX expects to release pivotal progression-free survival [PFS] data for ozekibart + FOLFIRI in heavily pretreated metastatic colorectal cancer in 2026. Ozekibart is also advancing in Ewing Sarcoma, with enrollment completion expected Q2 2026 and potential FDA meeting for accelerated approval in H2 2026.

Seeking Alpha • Jan 13, 2026

Why Inhibrx's Recent Strength May Not Be Built to Last

Inhibrx (NASDAQ: INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in a short span, drawing significant investor attention.

Benzinga • Dec 24, 2025

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC) in combination with Keytruda. The Company also provided a brief progress update on the expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma.

PRNewsWire • Dec 16, 2025

Inhibrx Reports Third Quarter 2025 Financial Results

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

PRNewsWire • Nov 14, 2025

Inhibrx Announces Participation in Upcoming Scientific Conferences

SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry/Academia Precision Oncology & Radmed Symposium November 5 th, 2025 – La Jolla, California Title:  DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location:   The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting November 12 th – 15th, 2025 – Boca Raton, Florida Title: The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study Lead Author: Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer Research Format: Presentation Date: Friday, November 14th, 2025 Time: 8:30 AM – 10:00 AM Eastern Standard Time Location: The Boca Raton, Boca Raton, Florida Society for NeuroOncology (SNO) 2025 Annual Meeting November 19 th – 23rd, 2025 – Honolulu, Hawaii Title: The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ Format: Poster Presentation Date: Saturday, November 22 nd, 2025 Time: 4:45 pm – 6:00 PM Eastern Standard Time Location:  Hawaii Convention Center, Honolulu, Hawaii; Kamehameha Exhibit Hall II & III The presentation and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of each event.

PRNewsWire • Nov 4, 2025

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Inhibrx Biosciences, Inc. delivered strong phase 2 results for ozekibart (INBRX-109) in advanced chondrosarcoma, doubling progression-free survival over placebo. INBX plans to file a Biologics License Application for ozekibart in chondrosarcoma by Q2 2026, with expansion opportunities in colorectal cancer and Ewing sarcoma showing promise. Additional catalysts for INBX stock include upcoming data for INBRX-106, a hexavalent OX40 agonist, targeting HNSCC and NSCLC, expected in Q4 2025.

Seeking Alpha • Oct 24, 2025

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended trading.

Reuters • Oct 23, 2025

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo  Key secondary endpoints reinforce the primary benefit, demonstrating meaningful improvements in disease control and patient quality of life Inhibrx plans to file a BLA in Q2 of 2026 Interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates in difficult-to-treat, heavily pretreated patients Management to host conference call today at 1:30 p.m. Pacific Time, to review the topline results and ongoing cohorts SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.

PRNewsWire • Oct 23, 2025

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

– Event to be webcast live on Thursday, October 23, 2025 at 1:30 p.m. PT – SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m.

PRNewsWire • Oct 22, 2025